Skip to main content

People in the News: Lloyd Everson, Marc Kerlin, Philip Watts, Chet Dye, Richard Klausner, and More

Premium

In gearing up for the launch of its CLIA-certified next-generation sequencing based lab and diagnostics platform for personalizing cancer treatments, MolecularHealth has appointed a management team to run its newly opened US offices in Woodlands, Texas.

The management team will be headed by Lloyd Everson, who will be CEO of the US division of MolecularHealth. Marc Kerlin will be COO, Philip Watts will be general counsel, and Chet Dye will be chief development officer.

Everson joins MolecularHealth from US Oncology, where he was vice chairman and a member of its board of directors. Kerlin was most recently president and CEO and e+Cancer Care. Watts helped advance the business plan at US Physiatry and was employed at US Oncology for several years in various capacities, including general counsel. Dye was chief development officer at Solis Women's Health and also formerly national VP at US Oncology.


Illumina has appointed Richard Klausner as senior VP and chief medical officer. Klausner joins Illumina from The Column Group venture capital firm where he was managing partner. He was also previously the executive director for global health at the Bill and Melinda Gates Foundation and director of the National Cancer Institute from 1995 to 2001.

At Illumina, Klausner will report to CEO Jay Flatley and spearhead efforts to integrate genomics strategies in to mainstream medical practice.


Prometheus Laboratories appointed as its new CEO Lisa Miller, previously corporate VP at Agilent subsidiary Dako. Miller will take over for Cathy Kerzner, who has been serving as interim CEO of Prometheus.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.